THERAPEUTIC TARGETING OF RECURRENT CASTRATE RESISTANT PROSTATE CANCER BY ACK1 TYROSINE KINASE INHIBITOR (R)-9B
$860,586FY2021Defense Health AgencyDOD
Washington University, The
Investigators
View source on USAspending →THERAPEUTIC TARGETING OF RECURRENT CASTRATE RESISTANT PROSTATE CANCER BY ACK1 TYROSINE KINASE INHIBITOR (R)-9B · GrantIndex